Neil Cohen Biography and Net Worth

Director of Anchiano Therapeutics

Neil Cohen founded Israel Seed Partners.

He is on the board of UltraShape, Inc., BroadLight, Inc., Oclaro (New Jersey), Inc. and Chemomab Therapeutics Ltd.

In his past career he occupied the position of Chairman of Gibui Holdings Ltd., Managing Partner at Israel Seed Partners, Advisor at Iguana Healthcare Management LLC and Chief Executive Officer & Director at Anchiano Therapeutics Ltd.

He received an undergraduate degree and a graduate degree from the University of Oxford.

What is Neil Harris Cohen's net worth?: The estimated net worth of Neil Harris Cohen is at least $6.23 thousand as of November 16th, 2022. Mr. Cohen owns 2,500 shares of Anchiano Therapeutics stock worth more than $6,225 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Cohen may own. Learn More about Neil Harris Cohen's net worth.
How old is Neil Harris Cohen?: Mr. Cohen is currently 58 years old. There are 4 older executives and no younger executives at Anchiano Therapeutics. The oldest executive at Anchiano Therapeutics is Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer, who is 83 years old. Learn More on Neil Harris Cohen's age.
How do I contact Neil Harris Cohen?: The corporate mailing address for Mr. Cohen and other Anchiano Therapeutics executives is ONE KENDALL SQUARE BUILDING 400 SUITE 14-105, CAMBRIDGE MA, 02139. Anchiano Therapeutics can also be reached via phone at 857-259-4622 and via email at [email protected]. Learn More on Neil Harris Cohen's contact information.
Has Neil Harris Cohen been buying or selling shares of Anchiano Therapeutics?: Neil Harris Cohen has not been actively trading shares of Anchiano Therapeutics over the course of the past ninety days. Most recently, on Tuesday, March 16th, Neil Harris Cohen bought 2,409 shares of Anchiano Therapeutics stock. The stock was acquired at an average cost of $41.51 per share, with a total value of $99,997.59. Following the completion of the transaction, the director now directly owns 2,409 shares of the company's stock, valued at $99,997.59. Learn More on Neil Harris Cohen's trading history.

Neil Harris Cohen Insider Trading History at Anchiano Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/16/2021	Buy	2,409	$41.51	$99,997.59	2,409

Neil Harris Cohen Buying and Selling Activity at Anchiano Therapeutics

Anchiano Therapeutics Company Overview

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $2.49

$2.48

$2.68

50 Day Range

MA: $21.77

$2.82

$59.00

2 Week Range

Now: $2.49

$0.51

$10.55

Volume

93,530 shs

Average Volume

3,145,648 shs

Market Capitalization

$18.48 million

P/E Ratio

16.60

Dividend Yield

N/A

Beta

0.93